Efficacy of Rapamycin for Refractory Hemangioendotheliomas in Maffucci's Syndrome
Authors:
- 10 August 2012
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (23) , e213-e215
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agentsAngiogenesis, 2009
- Tumeurs et malformations vasculaires, classification anatomopathologique et imagerieAnnales de Chirurgie Plastique Esthétique, 2006
- The shortened disabilities of the arm, shoulder and hand questionnaire (Quick DASH): validity and reliability based on responses within the full-length DASHBMC Musculoskeletal Disorders, 2006
- Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivoOncogene, 2003
- Best Cases from the AFIPRadioGraphics, 2001
- Vascular tumors and vascular malformations: Evidence for an association☆, ☆☆Journal of the American Academy of Dermatology, 2000
- Antiangiogenesis Is Produced by Nontoxic Doses of VinblastineBlood, 1999
- Spindle Cell HemangioendotheliomaAmerican Journal of Surgical Pathology, 1996
- Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.The Journal of Antibiotics, 1975
- Maffucciʼs SyndromeJournal of Bone and Joint Surgery, 1973